Astal Laboratories Limited has reported a significant surge in consolidated revenue for the financial year ended March 31, 2026, driven by its manufacturing and trading operations. The company's board, meeting on May 30, 2026, approved the audited standalone and consolidated financial results for Q4FY26 and FY26. The filing includes a resubmission due to a typographical error in the earlier submission, accompanied by an unmodified auditor's report from Sathuluri & Co., Chartered Accountants.

For the full fiscal year FY26, the company recorded a consolidated total revenue of ₹24,934.88 lakh, a sharp increase from ₹6,435.61 lakh in the previous year. Profit after tax for the year stood at ₹1,470.94 lakh, compared to ₹892.53 lakh in FY25. On a standalone basis, revenue from operations for FY26 was ₹15,599.53 lakh, while profit after tax was ₹811.55 lakh.

Financial Performance Summary

The board also considered the appointment of an internal auditor for the financial year 2026-27. The trading window for designated persons and their immediate relatives, which had been closed since April 01, 2026, will reopen forty-eight hours after the conclusion of the board meeting. The financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Astral Laboratories Limited has confirmed full compliance with the Securities and Exchange Board of India (SEBI) regulations for the financial year ended March 31, 2026. The Annual Secretarial Compliance Report, submitted to BSE Limited, certifies that the listed entity adhered to the provisions of the SEBI Act, 1992, and the Securities Contracts (Regulation) Act, 1956, along with relevant circulars and guidelines.

The report, issued by M/s Mahendra Khandelwal & Co., Practicing Company Secretaries, examined the company's documents, records, and filings made to the stock exchanges. It confirmed that Astral Laboratories maintained a functional website with timely dissemination of information and accurate web-links as required under Regulation 27(2) of the LODR Regulations. The company also adopted and updated all applicable policies under SEBI Regulations with board approval.

During the review period, the company acquired a wholly owned material subsidiary, Sriven Pharmachem India Private Limited. The secretarial audit verified that disclosures regarding this and other subsidiaries were made in accordance with regulatory requirements. Additionally, the performance evaluation of the Board, Independent Directors, and Committees was conducted as prescribed.

The audit confirmed that none of the directors were disqualified under Section 164 of the Companies Act, 2013. The company also complied with regulations concerning related party transactions, obtaining prior approval from the Audit Committee where necessary. No actions were taken by SEBI or stock exchanges against the entity, its promoters, or directors during the financial year.

Compliance Status